Novel antigen peptide and uses thereof

Abstract

The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.

1 - 11 . (canceled) 
     
     
         12 . A method for producing genetically modified T lymphocytes, said method comprising the steps of:
 (a) stimulating PBMCs or tumor infiltrating lymphocytes obtained from a subject with at least one antigen peptide, wherein said antigen peptide comprises an amino acid motif having an amino acid sequence:   
       
         
           
                 
                 
               
                     
                   (SEQ ID NO: 2) 
                 
                     
                   VLVPPLPSL, 
                 
             
                
                
               
            
           
         
         wherein the amino acid sequence of the amino acid motif may differ from VLVPPLPSL by 1, 2 or 3 amino acids, 
         (b) enriching the population of T lymphocytes specific for the antigen peptide(s) used in (a), and 
         (c) optionally cloning said population of T lymphocytes specific for the antigen peptide(s) used in (a). 
       
     
     
         13 - 14 . (canceled) 
     
     
         15 . A method of treating cancer in a subject in need thereof, comprising the steps of
 (a) stimulating PBMCs or tumor infiltrating lymphocytes obtained from the subject with at least one antigen peptide, wherein said antigen peptide comprises an amino acid motif having an amino acid sequence:   
       
         
           
                 
                 
               
                     
                   (SEQ ID NO: 2) 
                 
                     
                   VLVPPLPSL, 
                 
             
                
                
               
            
           
         
         wherein the amino acid sequence of the amino acid motif may differ from VLVPPLPSL by 1, 2 or 3 amino acids, 
         (b) enriching the population of genetically modified T lymphocytes specific for the antigen peptide(s) used in (a), 
         (c) optionally cloning said population of genetically modified T lymphocytes specific for the antigen peptide(s) used in (a), and 
         (d) administering to the subject a therapeutically effective amount of a composition for adoptive therapy comprising the genetically modified T lymphocytes produced in (b) or (c).